Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Forge Therapeutics has built a proprietary platform called MAGNET (Metalloprotein-targeting Approach to Generating New Experimental Therapeutics) to discover novel-class anti-infectives. With a development candidate to treat infections caused by high-priority Gram-negative pathogens, Forge is advancing its portfolio with partners worldwide.
Lysando AG’s Artilysin platform technology is producing novel antimicrobial proteins with a unique mode of action and a wide range of applications, from human and veterinary medicine to the food and cosmetics industry. Lysando is licensing the technology to companies all around the world.
Cytophage has developed a versatile bacteriophage-based antibacterial and antiviral technology targeting human and agricultural infectious diseases. With lead programs in avian and swine bacterial infections and in COVID-19, the company is seeking to expand its partnership network.
Biofilms are a major contributor to the global challenge of antibiotic resistance. BioFilm Control is leading the way in eradicating the biofilm barrier and overcoming antibiotic resistance with compounds that have blockbuster potential.